Internal dosimetry studies of Lu-BBN-GABA-DOTA, as a cancer therapy agent, in human tissues based on animal data.

The goal of using radiopharmaceuticals for therapeutic purposes is twofold: first, the most damage to cancer cells and, second, the most negligible dose transfers to healthy tissues. As Lu has the potential to cure a wide range of malignancies due to its varied range of beta energies, Lu-BBN-GABA-DOTA has been developed for therapeutic applications. In addition, Lu-BBN-GABA-DOTA can be over-expressed on gastrin-releasing peptide (GRP) receptors of the prostate, breast, small cell lung cancer, gastric, and colon tumors.